Search

Displaying results 2941 - 2950 of 10000 in total
  1. Target

    Inter-alpha-trypsin inhibitor heavy chain H2

    go.drugbank.com/bio_entities/BE0009060
    TargetHumans

    May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are ...

    Synonyms: Inter-alpha-trypsin inhibitor complex component II
  2. Target

    Inter-alpha-trypsin inhibitor heavy chain H1

    go.drugbank.com/bio_entities/BE0009080
    TargetEnzymeHumans

    May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are ...

    Synonyms: Inter-alpha-trypsin inhibitor complex component III
  3. Drug

    Buspirone

    go.drugbank.com/drugs/DB00490
    ApprovedInvestigational

    [A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®. … [L7375] The potential use of buspirone in combination with [melatonin] in depression and cognitive impairment via promoting neurogenesis has also been investigated.[A181751]

  4. Drug

    Dasabuvir

    go.drugbank.com/drugs/DB09183
    Approved

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Dasabuvir as first line therapy … in combination with [DB09296], [DB09297], and [DB00503] for genotype 1b and with [DB00811] for genotype 1a of Hepatitis C [L852].

    Synonyms: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide
  5. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264768] Acoramidis has been in development since at least 2013. … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.

  6. Drug

    Trichloroethylene

    go.drugbank.com/drugs/DB13323
    Approved

    Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. … It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with heavy menstrual bleeding, anemia, abdominal pain and pressure, bloating, increased urinary frequency

  8. Drug

    Metiamide

    go.drugbank.com/drugs/DB08805
    Experimental

    Metiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.

  9. Drug

    Tinzaparin

    go.drugbank.com/drugs/DB06822
    ApprovedInvestigational

    This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. … It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons.

    Products: innohep 8.000 IE/0,4 ml Injektionslösung in einer Fertigspritze, innohep 10.000 IE/0,5 ml Injektionslösung in einer Fertigspritze
  10. Drug

    Levobunolol

    go.drugbank.com/drugs/DB01210
    Approved

    A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.